Department of Social and Behavioral Sciences, NYU School of Global Public Health, New York University, New York, New York.
Department of Social and Behavioral Sciences, NYU School of Global Public Health, New York University, New York, New York; Department of Population Health, NYU Grossman School of Medicine, New York University, New York, New York.
Am J Prev Med. 2022 Mar;62(3):422-426. doi: 10.1016/j.amepre.2021.08.016. Epub 2021 Dec 7.
Identifying racial differences in trends in prescription opioid use (POU) is essential for formulating evidence-based responses to the opioid epidemic. This study analyzes trends in the prevalence of POU and exclusive nonopioid analgesic use (ENA) by race-ethnicity.
The Medical Expenditure Panel Survey was used to examine analgesic use among civilian adults without cancer (age ≥18 years) between 1996 and 2017. The outcome classified individuals into 3 mutually exclusive categories of prescription analgesic use: no prescription analgesic, POU, and ENA. Analyses were conducted between December 2020 and April 2021.
Among 250,596 adults, baseline analgesic usage varied with race-ethnicity, where non-Hispanic Whites had the highest POU (11.9%), and it was as prevalent as ENA (11.3%). Non-Hispanic Blacks and Hispanics had lower POU at baseline (9.3% and 9.6%, respectively), and ENA exceeded POU. Subsequently, POU increased across race-ethnicity with concomitant decreases in ENA, eventually eclipsing ENA in Whites and Blacks but not among Hispanics. Although POU among Blacks became as prevalent as it was among Whites in the 2000s-2010s, POU among Hispanics remained lower than the other groups throughout the 2000s-2010s. After the adoption of prescribing limits, POU declined across race-ethnicity by comparable levels in 2016-2017.
Blacks and Hispanics were less likely to use opioids when they first became widely available for noncancer pain. Subsequently, POU displaced ENA among Whites and Blacks. Although POU is often associated with Whites, a significant proportion of the Black population may also be at risk. Finally, although lower POU among Hispanics may be protective of misuse, it could represent undertreatment.
识别处方阿片类药物使用(POU)趋势中的种族差异对于制定针对阿片类药物流行的循证应对措施至关重要。本研究分析了种族和民族之间 POU 和单独非阿片类镇痛药使用(ENA)的流行趋势。
使用医疗支出面板调查(MEPS)检查了 1996 年至 2017 年期间无癌症的成年平民(年龄≥18 岁)的镇痛剂使用情况。该结果将个体分为 3 个互斥的处方镇痛药使用类别:无处方镇痛药、POU 和 ENA。分析于 2020 年 12 月至 2021 年 4 月之间进行。
在 250,596 名成年人中,基线镇痛剂使用因种族和民族而异,其中非西班牙裔白人的 POU 最高(11.9%),与 ENA 一样普遍(11.3%)。非西班牙裔黑人和西班牙裔的 POU 基线较低(分别为 9.3%和 9.6%),ENA 超过 POU。随后,POU 在所有种族和民族中均增加,同时 ENA 减少,最终在白人和黑人群体中超过了 ENA,但在西班牙裔人群体中并未如此。尽管黑人的 POU 在 2000 年代至 2010 年代变得与白人一样普遍,但在 2000 年代至 2010 年代期间,西班牙裔的 POU 仍低于其他群体。在采用处方限制后,2016-2017 年,POU 在所有种族和民族中的下降水平相当。
当阿片类药物最初广泛用于非癌性疼痛时,黑人和西班牙裔不太可能使用阿片类药物。随后,POU 在白人和黑人群体中取代了 ENA。尽管 POU 通常与白人有关,但很大一部分黑人人口也可能面临风险。最后,尽管西班牙裔人群中 POU 较低可能具有预防滥用的作用,但它也可能代表治疗不足。